Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Deffered Revenue: 2021-2024

Historic Non-Current Deffered Revenue for Viridian Therapeutics, Inc.\DE (VRDN) over the last 4 years, with Dec 2024 value amounting to $284,000.

  • Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue fell 67.29% to $140,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $140,000, marking a year-over-year decrease of 67.29%. This contributed to the annual value of $284,000 for FY2024, which is 50.44% down from last year.
  • According to the latest figures from FY2024, Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue is $284,000, which was down 50.44% from $573,000 recorded in FY2023.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue registered a high of $1.1 million during FY2021, and its lowest value of $284,000 during FY2024.
  • Its 3-year average for Non-Current Deffered Revenue is $572,667, with a median of $573,000 in 2023.
  • Data for Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue shows a maximum YoY plummeted of 50.44% (in 2024) over the last 5 years.
  • Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue (Yearly) stood at $1.1 million in 2021, then decreased by 25.07% to $861,000 in 2022, then crashed by 33.45% to $573,000 in 2023, then crashed by 50.44% to $284,000 in 2024.